Study | Cohort enrolment | Total population | Follow-up | Primary outcome | Long-term outcomes | |
---|---|---|---|---|---|---|
population | Median time | |||||
Peek et al.[4] | 2001–2006 | 68 | 52 | 6 months | Death or severe disability at 6 months | Lung function evaluated with PFT, overall health status, HRQoL, depression and anxiety symptoms |
Lindén et al.[29] | Before 2009 | 37 | 21 | 26 (12–50) months | Pulmonary morphology (CT scan) | Lung function (PFT), pulmonary symptoms (SGRQ) |
Hodgson et al.[33] | 2009–2011 | 34 | 15 | 9 (8–19) months | HRQoL (SF-36) | Related ECMO complications, survival, discharge destination, return-to-work status |
Luyt et al.[31] | Winter 2009 | 67 | 12 | 12Â months | HRQoL (SF-36) | Symptoms and activities since hospital discharge, weight and muscle-strength testing, lung morphology (CT scan), anxiety and depression (HAD scale), symptoms of PTSD (IES) |
Schmidt et al.[6] | 2008–2012 | 140 | 67 | 17 (11–28) months | Factors associated with death at 6 months | HRQoL (SF-36 score), pulmonary symptoms (SGRQ), anxiety and depression (HAD scale), symptoms of PTSD (IES) |
Li et al.[30] | 2009–2012 | 29 | 8 | 12 months | Pulmonary morphology |